As on Thursday, UroGen Pharma Ltd (NASDAQ: URGN) started slowly as it slid -4.85% to $23.92, before settling in for the price of $25.14 at the close. Taking a more long-term approach, URGN posted a 52-week range of $3.42-$25.19.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 10.39%. Meanwhile, its Annual Earning per share during the time was 10.39%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -7.31%. This publicly-traded company’s shares outstanding now amounts to $46.78 million, simultaneously with a float of $42.91 million. The organization now has a market capitalization sitting at $1.12 billion. At the time of writing, stock’s 50-day Moving Average stood at $19.05, while the 200-day Moving Average is $14.05.
UroGen Pharma Ltd (URGN) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. UroGen Pharma Ltd’s current insider ownership accounts for 8.33%, in contrast to 91.37% institutional ownership. According to the most recent insider trade that took place on Oct 08 ’25, this organization’s Chief Financial Officer sold 2,203 shares at the rate of 16.85, making the entire transaction reach 37,121 in total value, affecting insider ownership by 2,280. Preceding that transaction, on Sep 08 ’25, Company’s Chief Medical Officer sold 871 for 19.11, making the whole transaction’s value amount to 16,645. This particular insider is now the holder of 149,025 in total.
UroGen Pharma Ltd (URGN) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.51 per share during the current fiscal year. UroGen Pharma Ltd’s EPS decrease for this current 12-month fiscal period is -7.31% and is forecasted to reach -0.72 in the upcoming year.
UroGen Pharma Ltd (NASDAQ: URGN) Trading Performance Indicators
Let’s observe the current performance indicators for UroGen Pharma Ltd (URGN). It’s Quick Ratio in the last reported quarter now stands at 3.79. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 11.60.
In the same vein, URGN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.46, a figure that is expected to reach -0.48 in the next quarter, and analysts are predicting that it will be -0.72 at the market close of one year from today.
Technical Analysis of UroGen Pharma Ltd (URGN)
Through scrutinizing the latest numbers posted by the [UroGen Pharma Ltd, URGN], it can be observed that its last 5-days Average volume of 1.55 million was better the volume of 1.46 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 87.52% While, its Average True Range was 66.63.
Raw Stochastic average of UroGen Pharma Ltd (URGN) in the period of the previous 100 days is set at 89.81%, which indicates a major rise in contrast to 81.96% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 1.75 that was higher than 1.14 volatility it exhibited in the past 100-days period.
